phellodendron amurense bark extract

extract of bark of the phellodendron, phellodendron amurense, rutaceae

CAS: 164288-52-2

Identification

Namephellodendron amurense bark extract
CAS Number164288-52-2
FDA UNIISearch

Regulatory

Physical Properties

Food Chemicals Codex Listed No

Cosmetic Information

CosIngcosmetic data
Cosmetic Usesskin conditioning

No sensory data available

Safety Information

Oral/Parenteral ToxicityNot determined
Dermal ToxicityNot determined
Inhalation ToxicityNot determined

GHS Classification

['GHS Classification in accordance with 29 CFR 1910 (OSHA HCS)', 'GHS Label elements, including precautionary statements']

Safety in Use

Categorycosmetic ingredient for skin conditioning
Recommendation for phellodendron amurense bark extract usage levels up tonot for fragrance use.
Recommendation for phellodendron amurense bark extract flavor usage levels up tonot for flavor use.

No supplier data available

Potential Uses

None Found

Natural Occurrence

phellodendron amurense

Synonyms

extract of bark of the phellodendron, phellodendron amurense, rutaceae phellodendron extract PubMed: Tolerance of Phellodendron amurense bark extract (Nexrutine®) in patients with human prostate cancer. PubMed: Palmatine inhibits growth and invasion in prostate cancer cell: Potential role for rpS6/NFκB/FLIP. PubMed: STAT3 down regulates LC3 to inhibit autophagy and pancreatic cancer cell growth. PubMed: Effect of Magnolia officinalis and Phellodendron amurense (Relora®) on cortisol and psychological mood state in moderately stressed subjects. PubMed: Phellodendron amurense bark extract prevents progression of prostate tumors in transgenic adenocarcinoma of mouse prostate: potential for prostate cancer management. PubMed: Natural products: potential for developing Phellodendron amurense bark extract for prostate cancer management. PubMed: Butanol fraction containing berberine or related compound from nexrutine inhibits NFkappaB signaling and induces apoptosis in prostate cancer cells. PubMed: Regulation of Cox-2 by cyclic AMP response element binding protein in prostate cancer: potential role for nexrutine. PubMed: Akt/cAMP-responsive element binding protein/cyclin D1 network: a novel target for prostate cancer inhibition in transgenic adenocarcinoma of mouse prostate model mediated by Nexrutine, a Phellodendron amurense bark extract.